Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data
2024 · BMC Cancer · 8 citations
https://doi.org/10.1186/s12885-024-11852-3
H
Huixian Zhang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
41
Papers
302
Citations
10
h-index
10
i10-index
Huixian Zhang is an academic researcher from Shanxi Agricultural University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Hepatocellular Carcinoma Treatment and Prognosis. The author has an h-index of 10, co-authored 35 publications.
ORCID: 0000-0002-6758-7243Papers by this author
worksPre‐ to post‐dialysis potassium gradient and mortality in patients on hemodialysis: A propensity‐matched analysis
2024 · Therapeutic Apheresis and Dialysis · 2 citations
https://doi.org/10.1111/1744-9987.14213
Additional file 2: of Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study
2019 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.8062739
Additional file 1: of Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study
2019 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.8062736
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat